These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

101 related items for PubMed ID: 5560869

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Bone marrow changes following chemotherapy for multiple myeloma--a clinicopathological study of biopsy cases.
    Kurihara K, Hill W, Burkhardt R, Kettner G, Hashimoto N.
    Nihon Ketsueki Gakkai Zasshi; 1987 Jul; 50(4):876-89. PubMed ID: 3687331
    [No Abstract] [Full Text] [Related]

  • 5. [Multiple myeloma].
    Wasastjerna C.
    Duodecim; 1974 Jul; 90(10):751-64. PubMed ID: 4605799
    [No Abstract] [Full Text] [Related]

  • 6. [Medical treatment of multiple myeloma].
    Astaldi G, Meardi G, Yalçin B.
    Cancro; 1973 Jul; 26(5):319-37. PubMed ID: 4793834
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases.
    Body JJ, Greipp P, Coleman RE, Facon T, Geurs F, Fermand JP, Harousseau JL, Lipton A, Mariette X, Williams CD, Nakanishi A, Holloway D, Martin SW, Dunstan CR, Bekker PJ.
    Cancer; 2003 Feb 01; 97(3 Suppl):887-92. PubMed ID: 12548591
    [Abstract] [Full Text] [Related]

  • 9. The cyclic use of multiple alkylating agents in multiple myeloma.
    Harley JB, Ramanan SV, Kim I, Thiagarajan PV, Chen JH, Gomez R, Koppel D, Hyde F, Gustke S, Krall J.
    W V Med J; 1972 Jan 01; 68(1):1-3. PubMed ID: 4500402
    [No Abstract] [Full Text] [Related]

  • 10. [Smoldering multiple myeloma].
    Zapatero A, Blanco L, Sevilla F, Fraile G, Montalbán C.
    Rev Clin Esp; 1985 May 01; 176(9):469-70. PubMed ID: 4023335
    [No Abstract] [Full Text] [Related]

  • 11. Melphalan and dexamethasone for patients with multiple myeloma who are not candidates for autologous stem cell transplantation.
    Sharma A, Lokeshwar N, Raina V, Mohanti BK, Kumar R.
    Natl Med J India; 2007 May 01; 20(3):121-4. PubMed ID: 17867615
    [Abstract] [Full Text] [Related]

  • 12. Immunoglobulin and chromosome abnormalities in multiple myeloma.
    Rosenberg EB, Liu CH, Yang SL, Wang CH, Hwang TS.
    Taiwan Yi Xue Hui Za Zhi; 1970 Aug 28; 69(8):399-404. PubMed ID: 4098498
    [No Abstract] [Full Text] [Related]

  • 13. A case of severe aplastic anemia secondary to treatment with lenalidomide for multiple myeloma.
    Dasanu CA, Alexandrescu DT.
    Eur J Haematol; 2009 Mar 28; 82(3):231-4. PubMed ID: 19018868
    [Abstract] [Full Text] [Related]

  • 14. [Relapse of multiple myeloma in extramedullary sites].
    Bairey O, Huminer D, Blickstein D, Sandbank Y, Shaklai M.
    Harefuah; 1993 May 02; 124(9):539-41, 600. PubMed ID: 8340001
    [Abstract] [Full Text] [Related]

  • 15. Bortezomib-induced Sweet syndrome.
    Knoops L, Jacquemain A, Tennstedt D, Theate I, Ferrant A, Van den Neste E.
    Br J Haematol; 2005 Oct 02; 131(2):142. PubMed ID: 16197442
    [No Abstract] [Full Text] [Related]

  • 16. [Multiple myeloma manifesting as cardiac insufficiency].
    Bennis A, Niang A, Lebbar K, Nafidi S, Zaid D, Tahiri A, Chraibi N.
    Ann Med Interne (Paris); 1999 Feb 02; 150(2):160-1. PubMed ID: 10392265
    [No Abstract] [Full Text] [Related]

  • 17. Newer treatment options for patients in first relapse. From the Multiple Myeloma Research Foundation.
    Richardson P.
    Oncology (Williston Park); 2006 May 02; 20(6):633-8. PubMed ID: 16773847
    [No Abstract] [Full Text] [Related]

  • 18. Aclarubicin in the treatment of multiple myeloma.
    Sezaki T, Adachi T, Ishii H, Asano K, Takahashi I, Kimura I.
    Jpn J Clin Oncol; 1984 Sep 02; 14(3):353-8. PubMed ID: 6384577
    [Abstract] [Full Text] [Related]

  • 19. Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease.
    Heider U, Hofbauer LC, Zavrski I, Kaiser M, Jakob C, Sezer O.
    Biochem Biophys Res Commun; 2005 Dec 16; 338(2):687-93. PubMed ID: 16216218
    [Abstract] [Full Text] [Related]

  • 20. [Therapy of blood protein disorders].
    Wuhrmann F.
    Clin Ter; 1970 May 31; 53(4):291-8. PubMed ID: 4990207
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.